Elpiscience Announces First Patient Dosed with ES102 in combination with Toripalimab in China
October 15,2021 PDF Version

Shanghai/Suzhou, China, October 15, 2021. Elpiscience Biopharma, a global clinical-stage biotech company focusing on the discovery and development of next-generation cancer immunotherapies, today announced that the first patient has been dosed in a Phase 1 dose-escalation study in patients with advanced solid tumors in combination with TUOYI® (toripalimab). Data from single-agent dose-escalation and expansion shown that ES102 was well tolerated with a favorable safety profile and had a sign of preliminary anti-cancer activity.


Dr. Steve Chin, M.D., CMO of Elpiscience, said “We are looking forward to seeing ES102 in combo with anti-PD-1 to provide significantly improved clinical benefit to patients with advanced solid tumors”.


About ES102:

ES102 is a hexavalent OX40 agonistic antibody with a unique “first-in-class” design developed by Elpiscience. The special design of ES102 allows for efficient OX40 agonism even in the absence of exogenous cross-linking. ES102 induces much strong immune activation compared to the conventional bivalent OX40 antibodies. It has demonstrated impressive single-agent anti-tumor efficacy and synergy with anti-PD1/PD-L1 agents in preclinical models and has shown a favorable safety profile and preliminary anti-cancer activity.


About Elpiscience Biopharma:

Elpiscience is a clinical-stage biopharmaceutical company focusing on innovating and developing the next generation of cancer immunotherapy. Elpiscience has developed a pipeline of globally innovative molecules, covering a wide range of targets with a particular focus on turning “cold” tumors “hot”. The company has four assets in the clinical stage (ES101, ES102, ES104 and ES002). Elpiscience’s sustainable pipeline forms a strong cornerstone for developing the next generation and more effective immunotherapies. Founded and managed by seasoned executives in the biopharma industry, Elpiscience is backed by renowned investors such as Lilly Asia Ventures, Hillhouse Capital, Hyfinity Investments, Greater Bay Area Homeland Development Fund, CDH, Cormorant Asset Management and Superstring Capital. Elpiscience endeavors to advance at least one potentially innovative or differentiated global molecule into the clinic each year, providing clinical benefits to cancer patients worldwide.

Contact Us

Corporate Communications:

Investor Relation: